News
Important Only
Morning News Call - Canada, January 12
To access a PDF version of this newsletter, please click hereYou can read Morning News Call Canada via TOPNEWS Canada page.If you would like to receive this newsletter through your email, please register at:https://solutions.lseg.com/MorningNewsCallEN-subscription-pageEX-DIVIDENDSOrla Mining Ltd: Am...Reuters
Mon, Jan 12
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones
Jan 12 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY PROVIDES UPDATES ON CHRONIC HEPATITIS DELTA AND ONCOLOGY PROGRAMS AND UPCOMING 2026 CLINICAL MILESTONESVIR BIOTECHNOLOGY INC: POSITIVE, UPDATED PHASE 2 SOLSTICE DATA SHOWED COMBINATION OF TOBEVIBART AND ELEBSIRAN IS WELL TOLERATEDReuters
Mon, Jan 12
Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-Dees
Jan 12 (Reuters) - Praxis Precision Medicines Inc PRAX.O:PRAXIS PRECISION MEDICINES INC - TWO NDA SUBMISSIONS EXPECTED BY MID-FEB 2026 FOR ULIXACALTAMIDE IN ESSENTIAL TREMOR & RELUTRIGINE IN SCN2A/8A-DEESReuters
Mon, Jan 12
Xanadu Strengthens Executive Leadership With Appointment Of Chief Financial Officer And Chief Legal Officer
Jan 12 (Reuters) - Crane Harbor Acquisition Corp CHAC.O:XANADU STRENGTHENS EXECUTIVE LEADERSHIP WITH APPOINTMENT OF CHIEF FINANCIAL OFFICER AND CHIEF LEGAL OFFICERXANADU QUANTUM TECHNOLOGIES: APPOINTS MICHAEL TRZUPEK AS CFO AND NATALIE WILMORE AS CLOReuters
Mon, Jan 12
Geron Corporation Provides 2026 Financial Guidance
Jan 12 (Reuters) - Geron Corp GERN.O:ORATION PROVIDES 2026 FINANCIAL GUIDANCE2026 RYTELO (IMETELSTAT) NET PRODUCT REVENUE EXPECTED IN THE RANGE OF $220 TO $240 MILLION"OUR ANTICIPATED 2026 TOTAL OPERATING EXPENSE BASE REFLECTS OUR RECENT STRATEGIC RESTRUCTURING"2026 OPERATING EXPENSES EXPECT...Reuters
Mon, Jan 12
Abercrombie & Fitch Co. Provides Fourth Quarter And Fiscal Year Outlook Update
Jan 12 (Reuters) - Abercrombie & Fitch Co ANF.N:. PROVIDES FOURTH QUARTER AND FISCAL YEAR OUTLOOK UPDATEEXPECTS FY 2025 NET SALES GROWTH OF 6%OUTLOOK FY2025 NET INCOME PER DILUTED SHARE IN RANGE OF $10.30 TO $10.40OUTLOOK FY2025 SHARE REPURCHASES AROUND $450 MILLIONOUTLOOK Q4 NET SALES GROWTH AR...Reuters
Mon, Jan 12
Mdxhealth Reports Preliminary Fourth Quarter And Full Year 2025 Revenues, Issues 2026 Revenue Guidance, And Amends Earnout Terms With Exact Sciences
Jan 12 (Reuters) - MDxHealth SA MDXH.O:MDXHEALTH REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 REVENUES, ISSUES 2026 REVENUE GUIDANCE, AND AMENDS EARNOUT TERMS WITH EXACT SCIENCESMDXHEALTH SA - ISSUES 2026 REVENUE GUIDANCE OF $137-$140 MILLIONMDXHEALTH SA: EXPECTS TO REPORT Q4 REVENUE ABOUT...Reuters
Mon, Jan 12
Solid Biosciences Doses First Participant In First-In-Class Phase 1B Falcon Trial Evaluating Sgt-212 Dual-Route Gene Therapy For The Treatment Of Friedreich’S Ataxia
Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O:SOLID BIOSCIENCES DOSES FIRST PARTICIPANT IN FIRST-IN-CLASS PHASE 1B FALCON TRIAL EVALUATING SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIASOLID BIOSCIENCES INC: EXPECT TO SHARE AN INITIAL DATA UPDATE IN SECOND HALF OF 2026Reuters
Mon, Jan 12
Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)
Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL)ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER (CRL)ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONS...Reuters
Mon, Jan 12
Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule
Jan 12 (Reuters) - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS INC - SKYLINE TRIAL IN UC COMPLETES SPY001 ENROLLMENT AHEAD OF SCHEDULESPYRE THERAPEUTICS INC - SKYWAY TRIAL READOUTS EXPECTED IN 4Q 2026SPYRE THERAPEUTICS INC: SKYLINE PART A READOUTS ACCELERATED, NOW EXPECTED TO START IN Q2Reuters
Mon, Jan 12
Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027
Jan 12 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS INC - AKB-097 PHASE 2 RARE KIDNEY DISEASE BASKET TRIAL SCHEDULED TO BEGIN IN 2H 2026 WITH INITIAL DATA EXPECTED IN 2027Reuters
Mon, Jan 12
Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thrombocythemia
Jan 12 (Reuters) - PharmaEssentia Corp 6446.TW:PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 2B DATA FROM EXCEED-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT FOR ESSENTIAL THROMBOCYTHEMIAReuters
Mon, Jan 12
Satellogic Signs $18Mm USD Agreement With Portugal To Deliver Two Mark V High-Resolution Satellites
Jan 12 (Reuters) - Satellogic Inc SATL.O:SATELLOGIC SIGNS $18MM USD AGREEMENT WITH PORTUGAL TO DELIVER TWO MARK V HIGH-RESOLUTION SATELLITESSATELLOGIC SIGNS $18MM USD AGREEMENT WITH PORTUGAL TO DELIVER TWO MARK V HIGH-RESOLUTION SATELLITESReuters
Mon, Jan 12
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook
Jan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PROVIDES 2026 CORPORATE OUTLOOKBICARA THERAPEUTICS - EXPECTS TO ACHIEVE SUBSTANTIAL ENROLLMENT IN FORTIFI-HN01 IN 2026 TO ENABLE INTERIM ANALYSIS IN MID-2027BICARA THERAPEUTICS INC - ANTICIPATES ...Reuters
Mon, Jan 12
